Last updated on December 2016

cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China


Brief description of study

The purpose of this study is to evaluate the mutation pattern of epidermal growth factor receptor (EGFR) and other TKI targeted gene during TKI treatment of advanced NSCLC patient with liquid biopsy.

Detailed Study Description

In the study, 200 advanced NSCLC patients will be recruited. All the patients will receive biopsy genotype assay and Circulating Single-Molecule Amplification and Resequencing Technology (cSMART) liquid biopsy. those patients who carry EGFR activating mutation and other TKI targeted activating mutation will receive TKI treatment. During the TKI treatment, every patients will take liquid biopsy assay to monitor the mutation status. the study will be ended when all the patients had a progressive disease (PD) in their targeted lesion

Clinical Study Identifier: NCT02980536

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Hua Zhang, MS

Baogang Hospital
Baotou, China
  Connect »

Xiaohong Wang, MD

Baotou Cancer Hospital
Baotou, China
  Connect »

Fengyun Wang, MD

Northern Hospital Baotou
Baotou, China
  Connect »

Shubing Wang, MD

Baotou Centry Hospital
Baotou, China
  Connect »

Xiaoyu Shi, MD

Bayan Nur Hospital
Bayan Nur, China
  Connect »

Xiaoqiong Jia, MD

The Inner Mongolia Autonomous Region Cancer Hospital
Hohhot, China
  Connect »

Hui Li, MD

The Inner Mongolia Autonomous Region People's Hospital
Hohhot, China
  Connect »

Xiuhua Fu, MD

The First Affiliated Hospital of Inner Monglia Medical University
Hohhot, China
  Connect »

Qiong Qin, MD

Dalad Banner People's Hospital
Ordos, China
  Connect »